vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and VINCE HOLDING CORP. (VNCE). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $85.1M, roughly 1.0× VINCE HOLDING CORP.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 6.2%). VINCE HOLDING CORP. produced more free cash flow last quarter ($-5.7M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.3%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
VINCE. is a contemporary clothing fashion brand founded in 2002. In 2023 Authentic Brands Group purchased its intellectual property in a $76.5 million deal.
IOVA vs VNCE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $85.1M |
| Net Profit | — | $2.7M |
| Gross Margin | 67.4% | 49.2% |
| Operating Margin | -84.7% | 6.4% |
| Net Margin | — | 3.2% |
| Revenue YoY | 17.7% | 6.2% |
| Net Profit YoY | — | -37.3% |
| EPS (diluted) | — | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $85.1M | ||
| Q3 25 | $67.5M | $73.2M | ||
| Q2 25 | $60.0M | $57.9M | ||
| Q1 25 | $49.3M | $80.0M | ||
| Q4 24 | $73.7M | $80.2M | ||
| Q3 24 | $58.6M | $74.2M | ||
| Q2 24 | $31.1M | $59.2M | ||
| Q1 24 | $715.0K | $75.3M |
| Q4 25 | — | $2.7M | ||
| Q3 25 | $-91.3M | $12.1M | ||
| Q2 25 | $-111.7M | $-4.8M | ||
| Q1 25 | $-116.2M | $-28.3M | ||
| Q4 24 | — | $4.3M | ||
| Q3 24 | $-83.5M | $569.0K | ||
| Q2 24 | $-97.1M | $4.4M | ||
| Q1 24 | $-113.0M | $-4.7M |
| Q4 25 | 67.4% | 49.2% | ||
| Q3 25 | 43.0% | 50.4% | ||
| Q2 25 | 5.5% | 50.3% | ||
| Q1 25 | -0.8% | 50.1% | ||
| Q4 24 | 68.7% | 50.0% | ||
| Q3 24 | 46.2% | 47.4% | ||
| Q2 24 | -0.8% | 50.6% | ||
| Q1 24 | — | 45.4% |
| Q4 25 | -84.7% | 6.4% | ||
| Q3 25 | -140.7% | 15.2% | ||
| Q2 25 | -189.8% | -7.7% | ||
| Q1 25 | -245.8% | -37.1% | ||
| Q4 24 | -117.5% | 7.2% | ||
| Q3 24 | -152.1% | 1.5% | ||
| Q2 24 | -327.6% | 9.5% | ||
| Q1 24 | -16464.6% | -2.2% |
| Q4 25 | — | 3.2% | ||
| Q3 25 | -135.3% | 16.5% | ||
| Q2 25 | -186.2% | -8.3% | ||
| Q1 25 | -235.5% | -35.5% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | -142.7% | 0.8% | ||
| Q2 24 | -312.2% | 7.4% | ||
| Q1 24 | -15800.8% | -6.2% |
| Q4 25 | — | $0.21 | ||
| Q3 25 | — | $0.93 | ||
| Q2 25 | $-0.33 | $-0.37 | ||
| Q1 25 | $-0.36 | $-2.25 | ||
| Q4 24 | $-0.24 | $0.34 | ||
| Q3 24 | $-0.28 | $0.05 | ||
| Q2 24 | $-0.34 | $0.35 | ||
| Q1 24 | $-0.42 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $1.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $53.4M |
| Total Assets | $913.2M | $246.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $1.1M | ||
| Q3 25 | $300.8M | $777.0K | ||
| Q2 25 | $301.2M | $2.6M | ||
| Q1 25 | $359.7M | $607.0K | ||
| Q4 24 | $323.8M | $892.0K | ||
| Q3 24 | $397.5M | $711.0K | ||
| Q2 24 | $412.5M | $739.0K | ||
| Q1 24 | $356.2M | $357.0K |
| Q4 25 | $698.6M | $53.4M | ||
| Q3 25 | $702.3M | $49.3M | ||
| Q2 25 | $698.5M | $37.2M | ||
| Q1 25 | $767.9M | $41.8M | ||
| Q4 24 | $710.4M | $57.1M | ||
| Q3 24 | $773.5M | $52.4M | ||
| Q2 24 | $768.5M | $51.7M | ||
| Q1 24 | $680.0M | $47.2M |
| Q4 25 | $913.2M | $246.0M | ||
| Q3 25 | $904.9M | $239.0M | ||
| Q2 25 | $907.4M | $218.0M | ||
| Q1 25 | $966.7M | $222.7M | ||
| Q4 24 | $910.4M | $254.7M | ||
| Q3 24 | $991.1M | $253.6M | ||
| Q2 24 | $964.3M | $223.1M | ||
| Q1 24 | $869.8M | $225.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-5.1M |
| Free Cash FlowOCF − Capex | $-61.9M | $-5.7M |
| FCF MarginFCF / Revenue | -71.3% | -6.7% |
| Capex IntensityCapex / Revenue | 10.7% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -1.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $4.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $-5.1M | ||
| Q3 25 | $-78.7M | $4.2M | ||
| Q2 25 | $-67.4M | $-11.8M | ||
| Q1 25 | $-103.7M | $22.7M | ||
| Q4 24 | $-73.3M | $6.4M | ||
| Q3 24 | $-59.0M | $-3.2M | ||
| Q2 24 | $-98.4M | $-3.9M | ||
| Q1 24 | $-122.3M | $14.8M |
| Q4 25 | $-61.9M | $-5.7M | ||
| Q3 25 | $-89.5M | $2.1M | ||
| Q2 25 | $-74.9M | $-13.2M | ||
| Q1 25 | $-109.9M | $21.2M | ||
| Q4 24 | $-77.5M | $5.1M | ||
| Q3 24 | $-61.3M | $-3.9M | ||
| Q2 24 | $-98.9M | $-4.6M | ||
| Q1 24 | $-126.5M | $14.2M |
| Q4 25 | -71.3% | -6.7% | ||
| Q3 25 | -132.7% | 2.9% | ||
| Q2 25 | -124.9% | -22.9% | ||
| Q1 25 | -222.8% | 26.5% | ||
| Q4 24 | -105.1% | 6.4% | ||
| Q3 24 | -104.6% | -5.2% | ||
| Q2 24 | -317.9% | -7.8% | ||
| Q1 24 | -17685.3% | 18.9% |
| Q4 25 | 10.7% | 0.7% | ||
| Q3 25 | 16.1% | 2.9% | ||
| Q2 25 | 12.4% | 2.5% | ||
| Q1 25 | 12.6% | 1.9% | ||
| Q4 24 | 5.7% | 1.6% | ||
| Q3 24 | 3.9% | 0.9% | ||
| Q2 24 | 1.4% | 1.3% | ||
| Q1 24 | 583.4% | 0.7% |
| Q4 25 | — | -1.86× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.48× | ||
| Q3 24 | — | -5.61× | ||
| Q2 24 | — | -0.89× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
VNCE
| Vince Wholesale | $52.0M | 61% |
| Vince Direct To Consumer | $33.1M | 39% |
